Prevalence of CYP2C19 Gene Polymorphism in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Information image
Average (ratings)
No ratings
Your rating



Published online:

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Objective: CYP2C19 is the hepatic enzyme involved in biotransformation of clopidogrel to its active metabolite. Polymorphism of CYP2C19 genes would jeopardise clopidogrel’s efficacy as an antiplatelet agent. We aim to gain genetic polymorphism data of the CYP2C19 gene from patients with coronary artery disease undergoing PCI.

Materials and methods: This is a descriptive cross-sectional population-based study on patients with coronary artery disease (CAD) undergoing PCI at Dr Kariadi General Hospital Semarang from March 2019 to March 2020.

Results: From 79 subjects, there were 53 (67.1%) with chronic CAD and 26 (32.91%) with acute coronary syndromes. The frequency of CYP2C19*1 wild type allele was 77.8% (123), CYP2C19*2 681G>A gene was 20.9% (33), and CYP2C19*3 was 1.3% (2). We found CYP2C19*1/*2 genotype 25.31% (20 subjects) was higher than CYP2C19*1/*3 genotype of 1.26% (1). CYP2C19*2/*2 genotype frequency was 5.06% (4) and CYP2C19*3/*3 was 1.26% (1).

Conclusion: Prevalence of CYP2C19 gene polymorphisms in patients with CAD undergoing percutaneous coronary intervention at Dr Kariadi General Hospital Semarang consisted of 20.9% (33) with CYP2C19*2 681G>A genes and 1.3% (2) with CYP2C19*3 636G>A genes.